Chong Kun Dang Holdings Corp. (KRX:001630)
38,850
-150 (-0.38%)
At close: Sep 11, 2026
Chong Kun Dang Holdings Revenue
Chong Kun Dang Holdings had revenue of 251.17B KRW in the quarter ending June 30, 2026, with 3.71% growth. This brings the company's revenue in the last twelve months to 961.64B, up 1.43% year-over-year. In the year 2025, Chong Kun Dang Holdings had annual revenue of 959.01B with 0.13% growth.
Revenue (ttm)
961.64B
Revenue Growth
+1.43%
P/S Ratio
0.19
Revenue / Employee
27.48B
Employees
35
Market Cap
184.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 959.01B | 1.26B | 0.13% |
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewon Pharmaceutical | 614.64B |
| Samjin Pharmaceuticals | 274.03B |
| Whan In Pharm | 273.47B |
| JW Lifescience | 253.71B |
| HLB Pharmaceutical | 251.95B |
| Daihan Pharmaceutical | 216.55B |
| Yungjin Pharm. | 158.79B |
| REYON Pharmaceutical | 143.37B |